TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18981929

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)/endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
Number of subjects: 132

Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 132
Study: 18983669

Group type: EXPERIMENTAL
Intervention: New short uncemented, proximally fixed anatomic femoral implant
Number of subjects: 200
Study: 18983670

Group type: EXPERIMENTAL
Intervention: Immediate intervention protocol (IP) group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Delayed intervention protocol (DP) group (usual care for 6 months)
Number of subjects: 78
Study: 18986546

Group type: EXPERIMENTAL
Intervention: Dispatch-assisted CPR instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Before group (no dispatch-assisted CPR instructions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: After group (with dispatch-assisted CPR instructions)
Number of subjects: 0
Study: 18986547

Group type: EXPERIMENTAL
Intervention: Survey on CPR training and performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Final survey administered to the study population
Number of subjects: 0
Study: 18987294

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) INR testing using CoaguChek S device
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: POC INR testing in anemic patients
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: POC INR testing in nonanemic patients
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: POC INR testing from arteriovenous grafts
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: POC INR testing from dialysis catheters
Number of subjects: 37
Study: 18991508

Group type: EXPERIMENTAL
Intervention: Dental plaque biofilms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pseudomonas strains
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Respiratory pathogens isolated from the lung
Number of subjects: 100
Study: 18992649

Group type: EXPERIMENTAL
Intervention: MTWA non-negative (positive or indeterminate)
Number of subjects: 575

Group type: COMPARATOR
Intervention: MTWA negative
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: MTWA non-negative
Number of subjects: 575
Study: 18992650

Group type: EXPERIMENTAL
Intervention: Bioabsorbable everolimus-eluting coronary stent (BVS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Calcified plaques
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fibronecrotic plaques
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fibrocellular plaque
Number of subjects: 16
Study: 18997171

Group type: EXPERIMENTAL
Intervention: 2 UCB units
Number of subjects: 265

Group type: COMPARATOR
Intervention: 1 UCB unit
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: double UCBT
Number of subjects: 265

Group type: COMPARATOR
Intervention: single UCBT
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: grade II-IV acute GVHD
Number of subjects: 265
Study: 18997681

Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire (FFQ) for dietary intake assessment
Number of subjects: 93

Group type: COMPARATOR
Intervention: Plasma carotenoid concentrations
Number of subjects: 93
Study: 19001517

Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SSA) only (group A; n = 34)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery only (group C; n = 30)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery followed by SSA (group D; n = 16)
Number of subjects: 100

Group type: COMPARATOR
Intervention: SSA followed by surgery (group B; n = 20)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall SSA treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All patients receiving SSA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients not receiving SSA
Number of subjects: 100
Study: 19005394

Group type: EXPERIMENTAL
Intervention: Islet transplantation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exenatide therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single islet infusion or islet after kidney transplant
Number of subjects: 40

Group type: COMPARATOR
Intervention: Longer diabetes duration, higher insulin dosage, and occurrence of adverse events
Number of subjects: 40
Study: 19005970

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin C (358.0 mg/day)
Number of subjects: 133614

Group type: COMPARATOR
Intervention: Dietary antioxidants, carotenoids, and vitamin A
Number of subjects: 133614

Group type: COMPARATOR
Intervention: Dietary intake at baseline
Number of subjects: 133614

Group type: COMPARATOR
Intervention: Overall dietary intake of antioxidants
Number of subjects: 133614
Study: 19008157

Group type: EXPERIMENTAL
Intervention: Older HIV(+) subjects
Number of subjects: 0
Study: 19012935

Group type: EXPERIMENTAL
Intervention: Annexin A3 quantification in urine
Number of subjects: 591

Group type: COMPARATOR
Intervention: Percent free prostate specific antigen
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Annexin A3
Number of subjects: 591
Study: 19014833

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/d (with option to increase to 10 mg at weeks 4 and 8)
Number of subjects: 441
Study: 19015393

Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m² per day for 5 days for 6 cycles) and Rituximab (375 mg/m² per week for 8 infusions)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fludarabine and Rituximab
Number of subjects: 43
Study: 19018755

Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab tiuxetan (11.1 MBq/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab tiuxetan (14.8 MBq/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab tiuxetan
Number of subjects: 40
Study: 19019244

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (50 mg/day)
Number of subjects: 21657
Study: 19020433

Group type: EXPERIMENTAL
Intervention: II genotype
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ID genotype
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Genotype distribution
Number of subjects: 180
Study: 19020749

Group type: EXPERIMENTAL
Intervention: Cetuximab (anti-EGFR antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab (single agent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab + CDDP (optimal doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CDDP (cisplatin)
Number of subjects: 0
Study: 19023036

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study: 19025583

Group type: EXPERIMENTAL
Intervention: Group-based lifestyle counselling in addition to individual lifestyle counselling
Number of subjects: 2356

Group type: COMPARATOR
Intervention: Individual lifestyle counselling
Number of subjects: 2356
Study: 19025602

Group type: EXPERIMENTAL
Intervention: Cup feeding (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bottle feeding (n = 30)
Number of subjects: 60
Study: 19026265

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 153
Study: 19029442

Group type: EXPERIMENTAL
Intervention: KW-2449
Number of subjects: 0
Study: 19031925

Group type: EXPERIMENTAL
Intervention: CarolIReS camera
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intraoperative cameras
Number of subjects: 25
Study: 19032103

Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF), Abacavir (ABC), Lamivudine (3TC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: K65R and/or M184V mutations with wild-type virus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low level nucleoside reverse-transcriptase inhibitor-resistant HIV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixtures versus mutants in a clinical-isolate database
Number of subjects: 0
Study: 19032759

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: High-sensitive C-reactive protein (hsCRP)
Number of subjects: 871
Study: 19033011

Group type: EXPERIMENTAL
Intervention: Early abciximab (EA group: abciximab started before admission to cathlab, at least 30 minutes before balloon)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Late abciximab (LA group: periprocedural administration of abciximab in the cathlab)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Early abciximab (EA group)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Late abciximab (LA group)
Number of subjects: 1650
Study: 19037628

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GIP infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 19038036

Group type: EXPERIMENTAL
Intervention: Six-dose regimen of artemether-lumefantrine (AL) tablets
Number of subjects: 103
Study: 19038400

Group type: EXPERIMENTAL
Intervention: Common associated symptoms in patients with acute KD
Number of subjects: 198
Study: 19038879

Group type: EXPERIMENTAL
Intervention: 64-row, 0.5-mm multidetector CT angiography
Number of subjects: 291

Group type: COMPARATOR
Intervention: Conventional coronary angiography
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Per-vessel analysis of 866 vessels using multidetector CT angiography
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Disease severity assessed by CT and conventional angiography
Number of subjects: 291
Study: 19040767

Group type: EXPERIMENTAL
Intervention: Individually tailored programmes based on participants' individual assessment of their most important daily activities, implemented over 12 weeks and 24 weeks.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care and treatment provided to the control group.
Number of subjects: 55
Study: 19046447

Group type: EXPERIMENTAL
Intervention: Modified nitrogen washout/washin technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Helium dilution technique
Number of subjects: 30
Study: 19047220

Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine
Number of subjects: 61004

Group type: COMPARATOR
Intervention: Control group (diphtheria, tetanus, acellular pertussis vaccine and separate doses of hepatitis B and inactivated poliovirus vaccines)
Number of subjects: 61004
Study: 19047237

Group type: EXPERIMENTAL
Intervention: Surgical repair of pectus excavatum
Number of subjects: 264
Study: 19054318

Group type: EXPERIMENTAL
Intervention: Admission levels of activated factor XII type A (XIIaA)
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: XIIaA in the highest quartile
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: XIIaA
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: XIIaA in patients with admission TnT <= 0.05 ng mL(-1)
Number of subjects: 870
Study: 19055202

Group type: EXPERIMENTAL
Intervention: Exercise habits (self-reported); evaluated using the Paffenbarger Physical Activity and Exercise Index.
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Asthma control (measured by the Asthma Control Questionnaire); severity measured by the Severity of Asthma Scale.
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Education level and obesity status (independent variables in multivariate analysis).
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Meeting national exercise guidelines (20 to 30 minutes of exercise 3 to 5 days a week).
Number of subjects: 258

Group type: COMPARATOR
Intervention: Comparison with the general population regarding routine exercise.
Number of subjects: 258
Study: 19055703

Group type: EXPERIMENTAL
Intervention: MRI group (patients undergoing MRI scan)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control group (patients not undergoing MRI scan)
Number of subjects: 470
Study: 19055828

Group type: EXPERIMENTAL
Intervention: Higher fitness (measured as peak oxygen uptake during treadmill testing)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lower fatness (measured as percentage of total body fat by dual-energy x-ray absorptiometry)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Type 2 diabetes
Number of subjects: 217
Study: 19056591

Group type: EXPERIMENTAL
Intervention: 75 microg/kg methylcobalamin (2 times/wk) and 400 microg folinic acid (2 times/d) for 3 mo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control children (age-matched)
Number of subjects: 40
Study: 19057412

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for 12 weeks
Number of subjects: 168
Study: 19058002

Group type: EXPERIMENTAL
Intervention: Furazolidone 200 mg b.i.d, co-amoxiclav 1 g b.i.d., colloidal bismuth subcitrate 240 mg b.i.d., and esomeprazole 40 mg b.i.d. for 14 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Classical triple therapy (not specified in detail)
Number of subjects: 52
Study: 19061695

Group type: EXPERIMENTAL
Intervention: Combined CRT and ICD system
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: OptiVol fluid monitoring diagnostic data
Number of subjects: 1024
Study: 19064724

Group type: EXPERIMENTAL
Intervention: VAD-based induction chemotherapy followed by nonmyeloablative total body irradiation and allografting from an HLA-identical sibling
Number of subjects: 100
Study: 19067714

Group type: EXPERIMENTAL
Intervention: UVB treatments (6 to 9 sessions, 2 to 3 times weekly)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No treatment (untreated vitiliginous skin)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No treatment (untreated normal skin)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: UVB exposure (1 MED)
Number of subjects: 17
Study: 19068114

Group type: EXPERIMENTAL
Intervention: Mouthwash containing chlorine dioxide (ClO(2))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo mouthwash without chlorine dioxide
Number of subjects: 15
Study: 19068141

Group type: EXPERIMENTAL
Intervention: Interprofessional educational program for hypertension management involving physicians, nurses, and pharmacists.
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Immediate intervention group (experienced the intervention for at least 9 months).
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Delayed intervention group (not experienced the intervention yet).
Number of subjects: 5000
Study: 19070891

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (40-46 Gy in 20-25 daily fractions, treating five times a week)
Number of subjects: 905

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Combined data from ASTEC and EN.5 trials
Number of subjects: 905
Study: 19074928

Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 1767
Study: 19075070

Group type: EXPERIMENTAL
Intervention: Caspofungin at 25 mg/m(2) once daily as a 1-hour infusion
Number of subjects: 18
Study: 19076979

Group type: EXPERIMENTAL
Intervention: SR29142 at 0.15 mg/kg per day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SR29142 at 0.20 mg/kg per day
Number of subjects: 50
Study: 19077198

Group type: EXPERIMENTAL
Intervention: Screening and treatment of chlamydial infection via vaginal swabs tested by PCR, with treatment for those infected.
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Control group with vaginal swabs stored and analyzed after a year, without immediate treatment.
Number of subjects: 2500
Study: 19084893

Group type: EXPERIMENTAL
Intervention: Documentation of care plans discussion within the first 24 hours of hospitalization
Number of subjects: 17097

Group type: EXPERIMENTAL
Intervention: Patients with a code status discussion (CD)
Number of subjects: 17097

Group type: EXPERIMENTAL
Intervention: Site of enrollment
Number of subjects: 17097

Group type: EXPERIMENTAL
Intervention: Informal notations describing prehospital care wishes
Number of subjects: 17097

Group type: COMPARATOR
Intervention: Legal care planning documents (durable power of attorney)
Number of subjects: 17097
Study: 19084895

Group type: EXPERIMENTAL
Intervention: Involvement in discharge planning
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Awareness of community support services
Number of subjects: 403
Study: 19087147

Group type: EXPERIMENTAL
Intervention: Conservative treatment for degenerative cervical radiculopathy, specific modalities not detailed, duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis confirmed by magnetic resonance imaging (MRI).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electromyography (EMG) used to rule out other conditions.
Number of subjects: 0
Study: 19087222

Group type: EXPERIMENTAL
Intervention: NT-proBNP >300 pg/ml
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: D-dimer >2000 ng/ml
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: H-FABP >6 ng/ml
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: cTnI >0.09 ng/ml
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: myoglobin >70 ng/ml
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 146
Study: 19089707

Group type: EXPERIMENTAL
Intervention: Overall prevalence of obesity
Number of subjects: 2709

Group type: EXPERIMENTAL
Intervention: Overall prevalence of overweight
Number of subjects: 2709

Group type: COMPARATOR
Intervention: Comparison with national norms
Number of subjects: 2709
Study: 19092346

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with gemcitabine (1000 mg/m²) and cisplatin (50 mg/m²) for 4 bi-weekly cycles
Number of subjects: 28
Study: 19094074

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (ATG) 120 mg
Number of subjects: 26
Study: 19096013

Group type: EXPERIMENTAL
Intervention: R406, an inhibitor of Syk function, starting at 75 mg and escalating to 175 mg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: R406, an inhibitor of Syk function
Number of subjects: 16
Study: 19098313

Group type: EXPERIMENTAL
Intervention: Retinal electrical stimulation using epiretinal prostheses with two-dimensional electrode arrays.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychophysical techniques measuring brightness of electrically generated percepts.
Number of subjects: 0
Study: 19103636

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg infusion at baseline and day 15, with 100 mg methylprednisolone at each infusion)
Number of subjects: 8
Study: 19104367

Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal mesh repair (anterior repair with mesh)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal mesh repair (posterior repair with mesh)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal mesh repair (combined anterior and posterior mesh repair)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal mesh repair
Number of subjects: 261
Study: 19104368

Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal mesh surgery
Number of subjects: 105
Study: 19104516

Group type: EXPERIMENTAL
Intervention: Polypill intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19106083

Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy with ABCB1 TT genotype (two variant alleles at nucleotide 3435)
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy with CYP2C19 loss-of-function alleles (*2, *3, *4, or *5)
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy with CYP2C19 loss-of-function alleles among patients undergoing percutaneous coronary intervention
Number of subjects: 2208
Study: 19106084

Group type: EXPERIMENTAL
Intervention: Clopidogrel in healthy subjects (162 subjects)
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: Clopidogrel in acute coronary syndromes (1477 subjects)
Number of subjects: 1639
Study: 19106667

Group type: EXPERIMENTAL
Intervention: Tourniquet use when shock was absent
Number of subjects: 2838

Group type: EXPERIMENTAL
Intervention: Prehospital tourniquets
Number of subjects: 2838

Group type: EXPERIMENTAL
Intervention: Emergency department (ED) tourniquets
Number of subjects: 2838

Group type: COMPARATOR
Intervention: No tourniquet used
Number of subjects: 2838

Group type: EXPERIMENTAL
Intervention: Tourniquet use
Number of subjects: 2838
Study: 19109557

Group type: EXPERIMENTAL
Intervention: Tipifarnib (300-600 mg twice daily for 14 or 21 days) plus etoposide (100-200 mg daily on days 1-3 and 8-10)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tipifarnib (600 mg) plus etoposide (100 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tipifarnib (400 mg) plus etoposide (200 mg)
Number of subjects: 84
Study: 19112508

Group type: EXPERIMENTAL
Intervention: CagA seropositivity
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: CagA+ strains
Number of subjects: 526
Study: 19114617

Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 4615

Group type: EXPERIMENTAL
Intervention: High-risk individuals with NGT
Number of subjects: 4615

Group type: EXPERIMENTAL
Intervention: Individuals with impaired glucose regulation
Number of subjects: 4615
Study: 19114680

Group type: EXPERIMENTAL
Intervention: Caspofungin at 50 mg/m(2) once daily for 2 to 21 days (mean, 9.3 days)
Number of subjects: 9
Study: 19116237

Group type: EXPERIMENTAL
Intervention: HDL-apoA-I FCR in obese men
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: HDL-apoA-I FCR in nonobese men
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: VLDL-apoB PR and HOMA-IR score in obese men
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: VLDL-apoB PR and adiponectin in nonobese men
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: HDL-apoA-I FCR in both groups
Number of subjects: 87
Study: 19117345

Group type: EXPERIMENTAL
Intervention: Imatinib dose escalation to 600 mg or 800 mg daily
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Imatinib dose escalation based on protocol criteria
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Imatinib dose escalation based on ELN recommendations
Number of subjects: 106
Study: 19117867

Group type: EXPERIMENTAL
Intervention: World Health Organization growth standard
Number of subjects: 73

Group type: COMPARATOR
Intervention: Centers for Disease Control and Prevention growth curves
Number of subjects: 73

Group type: COMPARATOR
Intervention: Centers for Disease Control and Prevention charts
Number of subjects: 73
Study: 19117897

Group type: EXPERIMENTAL
Intervention: Neonatal infection (culture-proven sepsis, meningitis, necrotizing enterocolitis)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Count of 3 neonatal morbidities (bronchopulmonary dysplasia, brain injury, severe retinopathy)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Meningitis
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Infection or necrotizing enterocolitis
Number of subjects: 944

Group type: COMPARATOR
Intervention: No specific control group mentioned
Number of subjects: 944